Biocon Ltd will set up its first overseas manufacturing and research facility in Malaysia with an initial investment of around Rs 715 crore ($ 160 mn) .The USFDA-compliant plants would be operational by 2014 and make high-end biosimilars and biopharmaceuticals for the global market. It is said to be the biggest biotechnology investment in Malaysia. A large amount (of the present investment) would come from Pfizer's upfront payments ($200 million) and internal accruals. We also got good incentives from the Malaysian government.
In the next phase, Biocon would utilise the facility for production of anti-bodies and other biologics. The facility would also generate employment for close to 500 people in total, starting with 250 to 300 people in phase I. The investment follows a memorandum of agreement signed earlier this year between Biocon and BiotechCorp to manufacture bio-pharmaceutical products and formulations, enable the transfer of knowledge to Malaysia's human capital, and create employment.
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: